Click here - to use the wp menu builder

TFF Pharmaceuticals Raises $8.17 Million and Expands Leadership Team with New CFO and Director Appointments

AUSTIN, Texas–(BUSINESS WIRE)–TFF Pharmaceuticals announces completion of $8.17 Million Series A Preferred Stock; New Chief Financial Officer and Director are appointed.

http://www.businesswire.com/news/home/20190530005360/en/TFF-Pharmaceuticals-Raises-8.17-Million-Expands-Leadership/

TFF Pharmaceuticals Raises $8.17 Million and Expands Leadership Team with New CFO and Director Appointments

Recent Articles

Lilly to Supply the EU and EEA with up to 220,000 Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19

Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream, a Topical JAK Inhibitor, for the Treatment of Atopic Dermatitis (AD)

bluebird bio Submits Biologics License Application (BLA) to FDA for betibeglogene autotemcel (beti-cel) Gene Therapy for Patients With β-thalassemia Who Require Regular Red Blood...

LabGenius Appoints Dr. Didier Landais as Chief Operating Officer

Pfizer and BioNTech Expand Collaboration with U.S. to Provide 500 Million Additional COVID-19 Vaccine Doses at Not-for-Profit Price for Donation to Poorest Countries